clinical development strategy

3.31.2014 Clinical Development

Clinical Trial Management: Risk-Based Monitoring Represents Viable Oversight Solution

By Sarah Ray, Research Analyst With the growth in companies’ pipelines, clinical trial management becomes essential. One aspect of study oversight, monitoring trial risk, has evolved in recent years.  In traditional clinical studies, clinical...
 

1.30.2014 Biomarkers

Can a Video Game Diagnose and Treat Mental Health? Clinical Trials are Underway

By Natalie DeMasi, Research Analyst In today’s age, many people play video games to relieve stress, solve riddles, overcome challenges, conquer opponents and plain-old have fun.  But what if people could play video games as a form of medicine? ...
 

1.6.2014 Biomarkers

Pharma Gets Personal: The Cost of Personalized Medicine

By Victoria Cavicchi, Research Analyst The end of big pharma’s blockbuster era is often in the forefront of the industry’s strategic planning.  Healthcare’s focus has long reflected pharma’s focus on products with far-reaching effects. ...
 

12.23.2013 Clinical Development

Targeting the Alpha 7 Nicotinic Receptor May Be More Difficult Than Companies Originally Anticipated

By Sarah Ray, Research Analyst One of the characteristic symptoms of schizophrenia is patients’ inability to differentiate among important and unimportant stimuli in their environments.  Researchers attribute this symptom to a “P50 Auditory...
 

12.2.2013 Clinical Development

Clinical Teams Should Re-Think Risk-Based Monitoring to Improve Their Bottom Line

By Jennifer Harrell, Research Analyst Often, news surrounding the clinical development process seems pretty grim.  R&D budgets are being slashed, promising new compounds fall short in late-stage trials, patients struggle to find and enroll...
 

11.5.2013 Clinical Development

Expanding Schizophrenic Patients’ Treatment Options: A Look into Companies’ Clinical Pipelines

By Sarah Ray, Research Analyst Back in July, Biopharm Insight noted that a number of companies have drugs with new mechanisms of action (MoAs) that target patients’ negative and cognitive symptoms.  These compounds exist across various stages...
 

10.10.2013 Clinical Development

When Reinventing the Wheel Is a Good Thing: Developing New Mechanisms of Action to Target Unmet Medical Needs

By Sarah Ray, Research Analyst With another patent cliff looming, many pharmaceutical and biotechnology companies are expanding their clinical pipelines — be it to incorporate new therapies, to concentrate on niche areas or to develop new mechanisms...
 

7.23.2013 Lifecycle Management

From Phase 3 to Post-Marketing Studies: The Journey of Aripiprazole IM (Abilify Maintena)

By Sarah Ray, Research Analyst Schizophrenia is a complex psychological disease state that distorts patients’ cognitive and emotional responses. Patients may experience positive symptoms such as delusions, hallucinations or disorganized thought...
 

6.18.2013 Biomarkers

Potential Product May Ring True for Hearing-Loss and Tinnitus Patients

By Sarah Ray, Research Analyst When some people hear a ringing in their ears, perhaps they think someone is talking about them.  Or, in an office environment, they may equate the noise to the steady hum of fluorescent lights.  For many, this scenario...
 

6.4.2013 Clinical Development

Advisory Board Functions Expanding in Pharma Industry

By Jacob Presson, Research Analyst Advisory boards have been part of the pharmaceutical landscape for a long time, providing companies with valuable expert opinions on topics ranging from ensuring thorough regulatory submissions to clinical trial...